By:Ashling Wahner From: onclive.com Key Takeaways ctDNA testing is emerging as a key tool in breast cancer management, aiding in early detection and treatment monitoring. Ultra-sensitive assays like Signatera demonstrate high sensitivity and specificity in detecting distant relapses in breast cancer. ctDNA testing could enable treatment de-escalation or escalation based on MRD status, potentially transforming clinical practice. Despite current challenges, …
The Promise of ctDNA in Triple-Negative Breast Cancer
By: Amanda Brink, DNP, APRN, FNP-BC, AOCNP From: cancernursingtoday.com Patients and providers alike are becoming increasingly interested in the role of circulating tumor DNA (ctDNA) in predicting response to cancer treatment and assessing the risk of relapse. Although ctDNA is not yet routinely used in clinical practice for most patients with breast cancer, it holds significant promise, particularly in aggressive …
Real-World Data Tie Early Breast Cancer ctDNA to Recurrence, Lower OS
By: Jax DiEugenio From: oncnursingnews.com Findings from a real-world analysis using data from the Flatiron Health Research Database linked positive circulating tumor DNA (ctDNA) with lower overall survival (OS) and higher risk of recurrence in patients with early-stage breast cancer regardless of subtype, per a presentation at the 2025 American Society of Clinical Oncology Annual Meeting. Among 4,639 patients (2.4% …
ctDNA Helps Identify Targets in HR+, HER2- Metastatic Breast Cancer
From: targetedonc.com CASE SUMMARY A 56-year-old, postmenopausal woman presents with a palpable right breast mass with no clinically abnormal axillary lymph nodes. Core biopsy showed the patient had grade II invasive ductal carcinoma (IDC), was estrogen receptor-positive (ER+)/progesterone receptor-positive (PR+), and had HER2 immunohistochemistry (IHC) of 0; Ki-67 was at 33%. Lumpectomy and sentinel lymph node (SLN) biopsy showed a …
HR+ Breast Cancer: Role of Personalized Circulating Tumor DNA in Early Detection of Recurrences in Late Adjuvant Setting
By: Rosana Gnanajothy, MD From: medpagetoday.com The ability to use ctDNA as a ‘tumor marker’ for surveillance is an exciting theoretical concept The risk of recurrence remains after 5 years in HR-positive breast cancer. The role of assessing minimal residual disease (MRD) using circulating tumor DNA (ctDNA), and the ability to predict distant recurrences after 5 years of original diagnosis …
Blood-based Biomarkers Can Help To Predict Recurrence of Triple Negative Breast Cancer
Source: Indiana University School of Medicine From: technologynetworks.com Indiana University School of Medicine researchers Milan Radovich, PhD, and Bryan Schneider, MD, have discovered that the presence of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in the plasma of women’s blood who have undergone chemotherapy prior to surgery for the treatment of stage 1, 2 or 3 triple negative …